Author

S. Lu

h-index 14 View on Semantic Scholar

We have 4 of 61 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.

PURPOSE MET amplification accounts for up to 30% of acquired resistance to EGFR-TKI, especially following third-generation EGFR-TKI treatment, yet precision-targeted therapeutic options remain limited. Early-phase studies demonstrated promising antitumor activity with the MET-TKI dalmelitinib combined with the third-ge...

Zi-Ming Li, Xiao-Rong Dong, Yan Yu et al. · Journal of Clinical Oncology · 0 citations

Clinical trial Open access Sep 2026

AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer

Ociperlimab and tislelizumab±chemotherapy demonstrated a manageable safety profile and preliminary antitumor activity in patients with NSCLC or ES-SCLC and should be interpreted with caution.

Shun Lu, Yan Yu, Jun Zhang et al. · Journal for ImmunoTherapy of... · 0 citations

Open access Aug 2026

SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial.

Overall, SYS6010 shows a manageable safety profile and encouraging antitumor activity in previously treated, advanced NSCLC.

Zi-Ming Li, Zhen Zhou, Zhi-Yong He et al. · Cancer Cell · 0 citations

Case report Open access Sep 2026

Deep and durable response to re-challenge with platinum-based therapy in a platinum-relapsed small cell lung cancer patient following Olvi-Vec oncolytic immunotherapy: a case report

The role of Olvi-Vec as an oncolytic immunotherapy for cancer treatment warrants additional study, and the clinical effect observed in this patient may be related to Olvi-Vec-mediated changes in the tumor microenvironment, potentially leading to platinum re-sensitization.

Yun Chen, Zhi-Quan Qin, Zi-Ming Li et al. · Frontiers in Oncology · 0 citations